NMDA antagonist prodrugs
AssigneeAstraZeneca AB
InventorsGunnar Nordvall, Katharina Högdin, Per Jonas Malmborg, Annika Kers, Dirk Reinhold Weigelt, Peter Robert Bernstein, Michael Quirk, Michael Balestra
Life of this patent
Estimating the term…
Abstract
Prodrugs of an NMDA antagonist, (S)-1-phenyl-2-(pyridin-2-yl)ethanamine, useful for the treatment of depression (particularly major depressive disorder) or pain; compositions comprising them, and methods of making them.
Claims4
A compound that is tert-Butyl (S)-3-methyl-1-oxo-1-((S)-2-((S)-1-phenyl-2-(pyridin-2-yl)ethylcarbamoyl)pyrrolidin-1-yl)butan-2-ylcarbamate:
A method of making the compound, (S)-1-((S)-2-Amino-3-methylbutanoyl)-N-((S)-1-phenyl-2-(pyridin-2-yl)ethy)pyrrolidine-2-carboxamide dihydrochloride salt,
- comprising;
- reacting tert-Butyl (S)-3-methyl-1-oxo-1-((S)-2-((S)-1-phenyl-2-(pyridin-2-yl)ethylcarbamoyl)pyrrolidin-1-yl)butan-2-ylcarbamate:
- with hydrochloric acid to form a reaction product comprising said compound A.
Dependencies are inferred from the claim text.